Repeat vaccination against COVID-19: risk groups first, then everyone 12 and up The first invitations for a repeat vaccination against COVID-19 will be received by people in the Netherlands on 13 September 2022. RIVM will invite the oldest people first, and will then send an invitation to everyone aged 60 years and older.
Nearly one quarter of the Dutch population suffers from stomach, liver and/or bowel problems In 2019, nearly one in four people in the Netherlands had visited their general practitioner for stomach, liver and/or bowel problems of a more or less serious nature.
Use of Salvia divinorum may have adverse health effects The use of Salvia divinorum may have adverse health effects. Among other things, it may lead to hallucinations, restlessness, confusion, elevated heart rate and blood pressure, and psychosis.
Almost half of 9 and 10-year-olds get HPV vaccination at first opportunity This spring, more than 800,000 young people received an invitation to be vaccinated against HPV, the human papillomavirus.
Update on RIVM report “Silicone breast implants in the Netherlands”, State of Affairs October 2017 In June 2016, RIVM published the results of a study on breast implants in the Netherlands.
RIVM to contribute to new Horizon2020 project on oceans and human health across Europe A new EU Horizon2020 project Seas, Oceans and Public Health in Europe (SOPHIE) will explore the complex interplay between the health of the marine environment and that of humans.
Dutch collaboration in One Health European Joint Programme (EJP) RIVM, Wageningen Bioveterinary Research (WBVR) and the Netherlands Centre for One Health (NCOH) are involved in a recently granted One Health European Joint Programme which will start in January 20
Survey health complaints of women with a silicone breast implant This report provides a broad overview of the health complaints experienced by women with silicone breast implants in the Netherlands.
Efficiency and transparency of clinical drug trials must improve The efficiency and transparency of clinical drug trials in the Netherlands must improve. That concludes Sander van den Bogert in his PhD thesis ‘Trials & Tribulations.